Wyeth 2Q 2Q Revenues: $5.7 billion (-4%) 2Q Earnings: $1.3 billion (+13%) YTD Revenues: $11.1 billion (-5%) YTD Earnings: $2.5 billion (+7%) Comments: Excluding the unfavorable impact of foreign exchange, earnings were up 2% for the quarter and first half. Effexor sales were down 25% to $772 million in the quarter. Prevnar sales rose 24% to $783 million. Enbrel alliance revenue was $304 million (+7%), while Wyeth’s sales of Enbrel outside the U.S. and Canada were $736 million (+6%...